

1207

POSTER

Does cancer affect the divorce rate?

A. Syse¹, O. Kravdal². ¹Kreftregisteret, Dep. 1, Oslo, Norway; ²University of Oslo, Dep. of Economics, Oslo, Norway

Background: Cancer strikes the population in developed countries heavily. In Norway, between one-third and one-half of the population will ever be diagnosed with a malignant disease, and one-fourth of the deaths are reckoned as due to such diseases. Society's efforts are naturally directed towards improvements in cancer treatment and care, as well as prevention. Survival is, of course, the key issue for a cancer patient and his or her family. However, the quality of life among those who are about to fight the disease, or those who have apparently won the battle and survived, is also a legitimate concern. How are cancer survivors' chances of finding a spouse or partner, becoming parents, or having more children? Will their marital relationships take a turn for the better or worse? Knowledge of common responses may help individual patients and families plan their lives, and serve as an important basis for any societal attempts to assist. Our analyses explore how various cancer forms affect the probability of divorce in Norwegian couples. A malignant disease is an example of a completely unforeseen event that may change a marital relationship in many different ways, with a total impact that could go in either direction. We have not been able to find register-based studies of the probability of divorce following cancer illness, and our results may therefore be an important contribution in this field.

Materials and Method: Discrete-time hazard regression models were employed to register and census data on 1.4 million Norwegian married couples from 1974–2001 to explore the probability of divorce following cancer illness. Divorce rates for around 215 000 persons diagnosed with cancer were compared to divorce rates in otherwise similar persons (gender, age, period, educational level, number of children, and duration of marriage).

Results and Conclusions: No overall harmful influence of a cancer diagnosis was observed. Most cancer forms resulted in small, immediate declines in divorce rates the first years following diagnosis. Exceptions were a significant 40% increase in divorce probability for women diagnosed with cervical cancer, and a 20% immediate increase for men diagnosed with testicular cancer. Cervical and testicular cancers are illnesses encountered relatively early in adult life. At the same time, they are closely linked to intimacy and sexuality. Further research is needed to better understand the reason for the increased divorce risks seen for survivors of these cancer forms.

1208

POSTER

Age variation in cancer avoidability among European adults

I. Soerjomataram¹, E. de Vries¹, E. Pukkala², J.W.W. Coebergh¹.

¹Erasmus M.C., Public Health, Rotterdam, The Netherlands; ²Statistical and Epidemiological Cancer Research, Finish Cancer Registry, Helsinki, Finland

Introduction: Of the 1.4 million adult cases of major cancers in Europe, 50% could be potentially avoided. In this study we examined the proportion of avoidable cancers by age-group hence giving insight on causes of cancer and its preventability.

Methods: We estimated the potential in avoidable numbers and proportions of 11 cancers amenable to prevention (cancers of the oral cavity, oesophagus, stomach, colorectal, pancreas, laryngeal, lung, female breast, endometrium, kidney and bladder) in 28 European countries. We assumed that the aggregated rate of 3 countries with lowest incidence to be attainable throughout Europe. The difference between the age- and gender-specific national cancer incidence rates and the lowest rate observed in 2002 was determined and defined as "avoidable".

Results: Of the 684,000 adult male cases of selected cancers and countries within our study, 17,400 (74%), 53,800 (67%), 98,400 (60%) and 234,300 (56%) cases for males aged 15–44, 45–54, 55–64 and 65+, respectively, were hypothetically avoidable. The corresponding numbers for females were 24,900 (49%), 52,500 (50%), 71,900 (51%) and 212,700 (54%) of 687,000 female adult cases. Although the number of avoidable cases was largest in the oldest age group (447,500 cases among those aged 65 years or more), the younger age groups (15–44 and/or 45–54 years) harboured the highest relative proportions of avoidable cancers, 74% and 67% in males and 63% and 57% in females (excluding breast cancer), respectively. Among the younger age group, smoking-related cancers, such as oral cavity, larynx, lung and bladder cancer, exhibited the highest proportion of avoidability, ranging from 65% to 86%. Furthermore, we also observed a large variation in avoidable cancers for colorectal cancer among men, ranging from 81%, 52%, 54% and 52% for males aged 15–44, 45–54, 55–64 and 65+, respectively. This contrasts the observation for the female colorectal cancers where age variation in cancer avoidability was small.

Discussion: Cancer incidence among younger adults may be related to higher cancer susceptibility and its interaction with risk-increasing factors may be reflected in shorter latency times. In the excess of the smoking-related cancers adolescent exposure to smoking must play an important role. Hence early behavioral intervention is at utmost importance to reduce a large proportion cancer in all age groups including a significant proportion of cancers among the younger adults.

1209

POSTER

Dietary micronutrients in prediagnostic blood and survival from breast cancer

D. Gigineishvili¹, C.J. Newschaffer², S. Hoffman², G.W. Comstock², E.P. Norkus³, K.J. Helzlsouer². ¹Javakhishvili State University, Medicine Faculty, Tbilisi, Georgia; ²Bloomberg School of Public Health Johns Hopkins University, Department of Epidemiology, Baltimore MD, USA; ³Our Lady of Mercy Medical Center, Department of Biomedical Research, Bronx New York, USA

Background: Little is known regarding how prediagnostic levels of circulating micronutrients (total cholesterol, retinol, retinyl palmitate, alpha-tocopherol, gamma-tocopherol, lutein, beta-cryptoxanthin, lycopene, alpha-carotene, beta-carotene and total carotene) affect survival of women subsequently diagnosed with breast cancer.

Material and Methods: 292 white women from either the CLUE I or CLUE II cohorts diagnosed with first incident breast cancer between 1975 and 1994 was followed up through October 2001. CLUE I and II cohorts were established in 1974 and 1989, respectively, when volunteers in Washington County Maryland donated a blood sample to establish a research specimen bank. Out of 165 observed deaths, 63 were due to breast cancer. Cox proportional hazard models were used to estimate relative risks (hazard ratios HR) of breast cancer death associated with fourths of each micronutrient. Dummy variables were used to compare risk in second, third and upper fourths to the lowest fourth (based on cutpoints determined separately for 1974 and 1989 cohorts). Models were adjusted for age and cancer stage at diagnosis. Additional adjustment for other potential confounders (time between blood draw and diagnosis, hormone receptor status, cigarette smoking, marital status, menopausal status, age at first live birth, age at menarche, number of months lactation, family history of breast cancer, estrogen replacement therapy use, oral contraceptive use, and alcohol consumption) did not substantially change relationships between survival and micronutrient levels.

Results: No statistically significant associations between risk of dying and micronutrients concentration were found. However the HR estimates are suggestive of decreasing breast cancer mortality risk with increasing of pre-diagnostic beta-cryptoxanthin concentration (unadjusted and adjusted HR were 0.98, 0.78, 0.61; and 0.90, 0.67, 0.60 respectively). The dose dependant relationship, nonetheless, was not significant (p for trend=0.14 for unadjusted and p=0.153 for adjusted).

Conclusions: We did not observe any strong association between ten measured micronutrients and survival from breast cancer. Weak inverse association between risk of dying and beta-cryptoxanthin concentration raise the necessity of further researches which may clarify whether the dietary habits affect breast cancer progression in all stages. Supported by IARC fellowship and NIH grant UO1 CA/ES 6288.

1210

POSTER

Delay in cancer diagnosis – is there a problem?

R.P. Hansen¹, J. Søndergaard¹, H.T. Sørensen², F. Olesen¹. ¹The Research Unit for General Practice, University of Aarhus, Aarhus, Denmark; ²Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

Background: Delay in cancer diagnosis is the period between the patient's first cancer symptoms and onset of treatment and can be divided into patient delay, doctor delay and system (hospital) delay. A short diagnostic delay is a prerequisite for a better cancer prognosis. However, there is only little knowledge about the duration of and factors associated with diagnostic delay.

Materials and Methods: We conducted a cohort study in the County of Aarhus and included all newly diagnosed cancer patients during a 1-year period (about 3000 patients). Data were collected from administrative health care databases, hospital medical records and patient and general practitioner questionnaires (dates of diagnostic investigations, patient symptoms, specific patient and GP characteristics and GP-patient relationship).

Results: The median total delay was 100 days [95% CI: 95;105]. 25% of the patients experienced a median total delay of 173 days. Patient and system delay accounted for most of the delay (median 21 [21;28] and 57 days [55;60]). The median doctor delay was 0 days [0;0], but with